- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 16, Issue 22, 2010
Current Pharmaceutical Design - Volume 16, Issue 22, 2010
Volume 16, Issue 22, 2010
-
-
Editorial [Hot topic: Psychotropic Drugs in Child and Adolescent Psychiatry - a New Era on the Horizon (Executive Editors: Aribert Rothenberger, Manfred Gerlach and Ralf W. Dittmann)]
Authors: Aribert Rothenberger, Manfred Gerlach and Ralf W. DittmannFrontiers in child and adolescent psychopharmacology have moved forward in different aspects. Theoretical knowledge as well as practical experience have come to a point where summarizing and rethinking about steps ahead appears timely and necessary. On the one hand, the prescription rate of psychotropic drugs in children and adolescents has increased over the past decade and has led to many objections [ Read More
-
-
-
Safeguarding Children's Rights in Psychopharmacological Research: Ethical and Legal Issues
Objective: Research on psychopharmacological treatment in children and adolescents is the subject of ongoing ethical discussion, as minors with mental disorders constitute a vulnerable patient group. Considering the important legislative changes in pediatric research over the past decade in both the US and Western Europe, there is a need to review recent developments in this area. Method: Based on a systematic literature r Read More
-
-
-
Randomized Clinical Trials in Children - Ethical and Methodological Issues
Authors: A.D. Henschel, L.G. Rothenberger and J. BoosRandomization is an internationally accepted methodological tool used to perform sound clinical research. To ensure the clinical value of medical interventions, both evidence based medicine and new drug approvals require that randomized controlled trials (RCT) be conducted. Randomization prevents the manipulation of participant allocation and balances unknown confounders in a way no other method can. The gold standar Read More
-
-
-
Improving Medication Adherence in Chronic Pediatric Health Conditions: A Focus on ADHD in Youth
Authors: Anil Chacko, Jeffrey H. Newcorn, Nicole Feirsen and Jodi Z. UdermanChronic pediatric health conditions pose a significant challenge for youth, their families and professionals who treat these conditions. Long-term adherence to interventions, including and often-times, pharmacological interventions, is necessary but often problematic. Understanding factors related to poor adherence and intervening to improve adherence is essential in order to maximize long-term outcomes. Attention-deficit Read More
-
-
-
Stimulant Drug Effects on Attention Deficit/Hyperactivity Disorder: A Review of the Effects of Age and Sex of Patients
Authors: Christine Cornforth, Edmund Sonuga-Barke and David CoghillObjective: As dopamine functioning varies by sex and age it might be expected that the effects of methylphenidate or amfetamine, the psychostimulants used for the treatment of Attention Deficit /Hyperactivity Disorder (ADHD), will also be moderated by these factors. Here we review the published literature on whether stimulant effects in ADHD symptoms vary by age and sex. Method: We searched for studies p Read More
-
-
-
What can Actigraphy Add to the Concept of Labschool Design in Clinical Trials?
Pharmacological intervention with methylphenidate (MPH) is very common and helpful in the treatment of attention-deficit/ hyperactivity disorder (ADHD). It ameliorates inattention, impulsivity and hyperactivity and improves psychosocial functioning. The core symptoms of ADHD are problematic mainly in demanding structured situations such as in the classroom. It was argued that MPH does not only lead to a decreas Read More
-
-
-
The Pharmaceutical Economics of Child Psychiatric Drug Treatment
More LessOver the last decade, the number of health economic evaluations has increased substantially in the field of child psychiatry. The objective of the present paper is to offer an overview of economic evaluations of child psychiatric drug treatment. Major electronic databases, as well as abstract booklets from international clinical and health economics conferences with an external peer review process, were examined to search f Read More
-
-
-
Pharmacogenetic Approach for a Better Drug Treatment in Children
Authors: Guilherme Polanczyk, Marcelo P. Bigarella, Mara H. Hutz and Luis Augusto RohdeObjective: We conducted a systematic review of the literature aiming to identify original studies that have evaluated the effect of genes on the response to medications used to treat psychiatric disorders in children and adolescents. Results: We included 35 original studies on the pharmacogenetics of childhood psychiatric disorders. Thirty-three studies addressed the association between genes, particularly dopami Read More
-
-
-
Postnatal Brain Development and Psychotropic Drugs. Effects on Animals and Animal Models of Depression and Attention-Deficit/Hyperactivity Disorder
Authors: Nathalie Bock, Manfred Gerlach and Aribert RothenbergerIn recent years an increased use of psychotropic medication in children has been observed, but little is known about the influence of this medication on brain maturation. Probably, because of methodological problems and/or ethical aspects. It means that only naturalistic observational studies might allow to get some insight in humans. But even animal studies touching this issue are scarce and heterogeneous. Neverthel Read More
-
-
-
Novel and Current Treatment Concepts Using Pulmonary Drug Delivery
More LessThe novel technologies in pulmonary drug delivery propelled the development of new strategies for pharmacological intervention in human diseases. In particular, this review will focus on pulmonary parameters which influence the delivery of inhaled therapeutics and summarize novel applications and recent innovations. The central issues of pulmonary drug application are optimal effectiveness under conditions of grea Read More
-
-
-
Targeting the p53 Pathway of Apoptosis
Authors: Joana D. Amaral, Joana M. Xavier, Clifford J. Steer and Cecilia M.P. RodriguesThe tumor suppressor protein, p53 is regarded as a key player in tumor suppression, as it promotes growth arrest, apoptosis and cellular senescence, while also blocking angiogenesis. The plethora of mechanisms underlying the p53 efficient death response involves transcriptional activation or repression of target genes, as well as the recently identified microRNAs, and transcription-independent functions. Pathologi Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
- Issue 38
- Issue 37
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
